Compare Citius Pharmaceuticals Inc (CTXR) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Advanced Drainage Systems Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Advanced Drainage Systems Inc trades at $127.14 (market cap $9.52B). The key difference: Advanced Drainage Systems Inc is far larger — about 699× Citius Pharmaceuticals Inc's market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Advanced Drainage Systems Inc for 43 Days on average.
| CTXR | WMS | |
|---|---|---|
Market Cap | $13.62M | $9.52B |
Volume | 132,438 | 907,564 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $175.38 |
52-Week Low | $0.48 | $125.33 |
Typical Hold Time | 16 Days | 43 Days |
Enterprise Value | $3.79M | $11.12B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Advanced Drainage Systems (WMS) trades at $126.08, down 3.07% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.49 exceeding expectations. Revenue for 2025 was $2.90 billion, with a net income margin of 15.5%. The company maintains strong profitability metrics, including a 24.9% ROE, and recently announced a quarterly dividend. Analyst consensus is mixed with a $188.70 price target, while institutional activity shows both new acquisitions and reductions in holdings.
WMS presents a balanced outlook with solid fundamentals and recent earnings beats offset by near-term technical weakness. Investment opportunities include sustained revenue growth and margin expansion from operational efficiencies. Key risks involve competitive pressures in the construction sector and potential volatility from macroeconomic factors. The stock's current valuation at a P/E of 21.48 offers a reasonable entry point relative to growth prospects, but investors should monitor cash flow trends given the projected net cash outflow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
